ARS Pharmaceuticals, Inc Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2023
2022
2021
2020
2019
0M
-97.72%
0M
0M
67M
47M
20M
-68M
0M
-54M
0M
-54M
59.95%
68M
0M
-67M
0M
-68M
1M
-76.10%
17M
-16M
37M
18M
18M
-36M
1M
-35M
0M
-34M
67.90%
37M
0M
-35M
0M
-36M
6M
-69.13%
20M
-15M
25M
5M
20M
-19M
0M
-20M
0M
-20M
1,800.75%
25M
0M
-19M
0M
-19M
18M
-
14M
4M
18M
4M
14M
0M
0M
-1M
0M
-1M
-95.56%
18M
0M
0M
0M
0M
0M
-
2M
-2M
23M
0M
22M
-24M
0M
-24M
0M
-24M
-95.56%
24M
0M
-23M
0M
-24M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
4Q2021
3Q2021
2Q2021
1Q2021
0M
-100.00%
0M
0M
10M
7M
3M
-10M
0M
-7M
0M
-7M
-50.32%
10M
0M
-10M
-7M
-10M
0M
-100.00%
0M
0M
18M
15M
3M
-18M
0M
-15M
0M
-15M
125.54%
18M
0M
-18M
0M
-18M
0M
-97.84%
7M
-7M
21M
13M
7M
-21M
0M
-17M
0M
-17M
187.06%
21M
0M
-21M
0M
-21M
0M
-96.98%
7M
-7M
19M
12M
7M
-19M
4M
-15M
0M
-11M
51.45%
19M
0M
-19M
0M
-19M
1M
-
4M
-4M
15M
11M
5M
-15M
0M
-14M
0M
-14M
51.45%
15M
0M
-15M
0M
-15M
0M
-
0M
0M
7M
3M
4M
-7M
1M
-7M
0M
-7M
51.45%
7M
0M
-7M
0M
-7M
0M
-
4M
-4M
7M
2M
4M
-6M
0M
-6M
0M
-6M
51.45%
7M
0M
-6M
0M
-6M
1M
-
5M
-5M
8M
2M
5M
-7M
0M
-7M
0M
-7M
51.45%
8M
0M
-7M
0M
-7M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
51.45%
0M
0M
0M
0M
-5M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
51.45%
0M
0M
0M
0M
-5M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
51.45%
0M
0M
0M
0M
-4M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
51.45%
0M
0M
0M
0M
-4M